{{'Search' | translate}}
 

FITC anti-mouse/human CD11b Antibody

FITC anti-mouse/human CD11b 抗体

Company: BioLegend
Catalog#: 101206
Bio-protocol()
Company-protocol()
Other protocol()

Adhesion Assay for Murine Bone Marrow Hematopoietic Stem Cells
Author:
Date:
2017-02-20
[Abstract]  Hematopoietic stem cells (HSCs) are defined by their functional abilities to self-renew and to give rise to all mature blood and immune cell types throughout life. Most HSCs are retained in a non-motile quiescent state within a specialized protective microenvironment in the bone marrow (BM) termed the niche. HSCs are typically distinguished from other adult stem cells by their motility capacity. Movement of HSCs across the physical barrier of the marrow extracellular matrix and blood vessel endothelial cells is facilitated by suppression of adhesion interactions, which are essential to preserve the stem cells retained within their BM niches. Importantly, homing of HSCs to the BM following clinical transplantation is a crucial first step for the repopulation of ablated BM as in the case of ... [摘要]  造血干细胞(HSC)由其自我更新的功能定义,并在整个生命中产生所有成熟的血液和免疫细胞类型。大多数HSC在被称为利基的骨髓(BM)的专门的保护性微环境内保持在非运动性静止状态。 HSC通常通过其运动能力与其他成体干细胞区分开来。通过抑制粘附相互作用促进骨髓细胞外基质和血管内皮细胞的物理屏障的移动,这是保留在其BM细胞壁内保留的干细胞所必需的。重要的是,在临床移植后将HSC归巢到BM是重建消融BM的关键的第一步,就像血液恶性肿瘤治疗策略一样。归位过程结束于HSC的选择性访问和锚定到其在BM内的专门的位置。粘附分子是在干细胞移植的情况下增强归巢或减少BM保留以从匹配供体的血液中收集动员的HSC的靶标。在HSC上功能表达并参与其归巢和保留的主要粘附蛋白是整合素α4β1(非常晚的抗原-4; VLA4)。在该方案中,我们引入了针对表达VLA4的鼠骨髓干细胞优化的粘附测定。该测定法在分离表达VLA4的贴壁细胞后,通过流式细胞术与HSC富集细胞表面标记物定量粘附的HSC。

背景 HSCs主要保留在BM中,并通过与其微环境(niche)的粘合相互作用来调节。以这种方式,HSC保持在非运动性静止状态,保护它们免受DNA损伤代理(Boulais和Frenette,2015; Mendelson和Frenette,2014; ...

Quantification of Tumor Material Uptake
Author:
Date:
2016-10-20
[Abstract]  Extracellular tumor material including exosomes, microvesicles and apoptotic tumor debris may help cancers invade new organs. Enhancing the removal of extracellular tumor material by immune cells represents a novel immunotherapy approach for preventing cancer metastasis. This protocol quantifies the uptake and removal of extracellular tumor material from circulation and tissues by immune cells. In this assay fluorescent tumor cells are transferred into mice, and then immune cells are quantified by either flow cytometry or imaging cytometry for their uptake of tumor material. [摘要]  包括外来体,微泡和凋亡性肿瘤碎片的细胞外肿瘤材料可以帮助癌症侵入新器官。增强免疫细胞对细胞外肿瘤材料的去除代表了用于预防癌症转移的新型免疫治疗方法。该方案定量免疫细胞从循环和组织吸收和去除细胞外肿瘤物质。在该测定中,将荧光肿瘤细胞转移到小鼠中,然后通过流式细胞术或成像细胞计量术来定量免疫细胞对肿瘤材料的摄取。

[背景] 研究已经证明,包括从肿瘤脱落的外来体,微泡和凋亡性肿瘤碎片的细胞外肿瘤材料是肿瘤转移,生长和逃避免疫应答的重要介质(Vader等人,2014; Pucci和Pittet ,2013; Pucci等人,2016)。免疫细胞具有去除,应答和转运这种循环肿瘤材料的能力(Hanna等人,2015; Pucci等人,2016; Headley等人。,2016)。该协议提供了一种新的方法来量化特定免疫细胞群体的肿瘤材料摄取,并且可以适于测试调节肿瘤材料摄取的免疫靶标。该协议可以帮助更好地理解对细胞外肿瘤材料的免疫应答,希望最终开发针对癌症发展中的细胞外肿瘤材料的新疗法。

Comments